MedTrace Logo

Selumetinib for NF2-Related Schwannomatosis

NCT07707947 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-07-16

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate the efficacy and safety of the MEK1/2 inhibitor selumetinib in treating patients with neurofibromatosis type 2-related schwannomatosis (NF2-SWN), including both adults and children with inoperable or progressive tumors.

Conditions

  • Neurofibromatosis Type 2
  • NF2
  • NF2-related Schwannomatosis
  • Meningioma
  • Ependymoma
  • Vestibular Schwannoma

Interventions

DRUG

Selumetinib

Selumetinib will be administered at a dose of 25 mg/m²orally twice daily (BID),with a maximum single dose of 50 mg per administration.Doses will be calculated based on body surface area (BSA)and rounded to the nearest 5 mg increment.

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Beijing Tiantan Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
3 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-15
Primary Completion
2028-12-31
Completion
2028-12-31
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07707947 on ClinicalTrials.gov